Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
In 1986, Kärre and colleagues reported that natural killer (NK) cells rejected an MHC class I-deficient tumor cell line (RMA-S) but they did not reject the same cell line if it expressed MHC class I (RMA). Based on this observation, they proposed the concept that NK cells provide immune surveillance for “missing self,” e.g., they eliminate cells that have lost class I MHC antigens. This seminal observation predicted the existence of inhibitory NK cell receptors for MHC class I. Here, we present evidence that NK cells are able to reject tumors expressing MHC class I if the tumor expresses a ligand for NKG2D. Mock-transfected RMA cells resulted in tumor formation. In contrast, when RMA cells were transfected with the retinoic acid early inducible gene-1 γ or δ (RAE-1), ligands for the activating receptor NKG2D, the tumors were rejected. The tumor rejection was mediated by NK cells, and not by CD1-restricted NK1.1 + T cells. No T cell-mediated immunological memory against the parental tumor was generated in the animals that had rejected the RAE-1 transfected tumors, which succumbed to rechallenge with the parental RMA tumor. Therefore, NK cells are able to reject a tumor expressing RAE-1 molecules, despite expression of self MHC class I on the tumor, demonstrating the potential for NK cells to participate in immunity against class I-bearing malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“NKG2D has been implicated in immune surveillance of tumors using transgenic models of spontaneous cancer as well as subcutaneous tumor transfer models (Cerwenka et al., 2001; Diefenbach et al., 2001; Guerra et al., 2008).”
From p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells (2013) · cites this paper as Cerwenka et al., 2001
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 2,999
Self-citationBiology of Natural Killer Cells
Trinchieri, G. (1989) · Advances in Immunology · doi:10.1016/s0065-2776(08)60664-1 · Cited by 2,902
Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Kärre, K., Ljunggren, H. G., Piontek, G., & Kiessling, R. (1986) · Nature · doi:10.1038/319675a0 · Cited by 2,161
NATURAL KILLER CELLS IN ANTIVIRAL DEFENSE: Function and Regulation by Innate Cytokines
Biron, C. A., Nguyen, K. B., Pien, G. C., Cousens, L. P., & Salazar-Mather, T. P. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.189 · Cited by 2,113
Lanier, L. L. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.359 · Cited by 1,648
Self-citationCosman, D., Müllberg, J., Sutherland, C. L., Chin, W., Armitage, R., Fanslow, W., Kubin, M., & Chalupny, N. J. (2001) · Immunity · doi:10.1016/s1074-7613(01)00095-4 · Cited by 1,232
An Activating Immunoreceptor Complex Formed by NKG2D and DAP10
Wu, J., Song, Y., Bakker, A. B. H., Bauer, S., Spies, T., Lanier, L. L., & Phillips, J. H. (1999) · Science · doi:10.1126/science.285.5428.730 · Cited by 1,039
Self-citationBroad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB
Groh, V., Rhinehart, R., Secrist, H., Bauer, S., Grabstein, K. H., & Spies, T. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6879 · Cited by 1,028
Groh, V, Bahram, S., Bauer, S., Herman, A., Beauchamp, M., & Spies, T. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.22.12445 · Cited by 1,017
Costimulation of CD8αβ T cells by NKG2D via engagement by MIC induced on virus-infected cells
Groh, V., Rhinehart, R., Randolph-Habecker, J., Topp, M. S., Riddell, S. R., & Spies, T. (2001) · Nature Immunology · doi:10.1038/85321 · Cited by 951
Research works printed but not linked: 2
- 10.1146/annurev.iy.10.040192.001201 · doi:10.1146/annurev.iy.10.040192.001201 · Paper page
- S Bahram Adv Immunol 76, 1–60 (2000).
Cited by
Items 301–400 of 691
Immunobiology of naïve and genetically modified HLA-class-I-knockdown human embryonic stem cells
Deuse, T., Seifert, M., Phillips, N., Fire, A. Z., Tyan, D. B., Kay, M. A., Tsao, P. S., Hua, X., Velden, J., EIERMANN, T. H., et al. (2011) · Journal of Cell Science · doi:10.1242/jcs.087718 · Cited by 44
Barber, M. A., Zhang, T., Gagne, B. A., & Sentman, C. L. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.10.6140 · Cited by 45
Dhanji, S., Teh, S.-J., Oble, D. A., Priatel, J. J., & Teh, H. (2004) · Blood · doi:10.1182/blood-2004-01-0150 · Cited by 44
Tamaki, S., Kawakami, M., Yamanaka, Y., Shimomura, H., Imai, Y., Ishida, J., Yamamoto, K., Ishitani, A., Hatake, K., & Kirita, T. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.09.004 · Cited by 43
Tsukagoshi, M., Wada, S., Yokobori, T., Altan, B., Ishii, N., Watanabe, A., Kubo, N., Saito, F., Araki, K., Suzuki, H., et al. (2015) · Cancer Science · doi:10.1111/cas.12853 · Cited by 43
Schwaiger, T., Knittler, M. R., Grund, C., Angela, R. O.-O. O., Kapp, J., Lerch, M. M., Mettenleiter, T. C., Mayerle, J. V., & Blohm, U. (2017) · International Journal of Cancer · doi:10.1002/ijc.31026 · Cited by 43
Vahlne, G., Becker, S., Brodin, P., & Johansson, M. H. (2007) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2007.02026.x · Cited by 43
NKG2D-independent suppression of T cell proliferation by H60 and MICA
Kriegeskorte, A. K., Gebhardt, F. E., Porcellini, S., Schiemann, M., Stemberger, C., Franz, T. J., Huster, K. M., Carayannopoulos, L. N., Yokoyama, W. M., Colonna, M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502026102 · Cited by 43
Pollock, R. A., Chandran, V., Barrett, J., Eder, L., Pellett, F., Yao, C. M. K. L., Lino, M., Shanmugarajah, S., Farewell, V. T., & Gladman, D. D. (2011) · Tissue Antigens · doi:10.1111/j.1399-0039.2011.01670.x · Cited by 42
Intact NKG2D-Independent Function of NK Cells Chronically Stimulated with the NKG2D Ligand Rae-1
Champsaur, M., Beilke, J. N., Ogasawara, K., Koszinowski, U. H., Jonjić, S., & Lanier, L. L. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000397 · Cited by 42
Self-citationCancer vaccine development: on the way to break immune tolerance to malignant cells
Mocellin, S., Rossi, C. R., & Nitti, D. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.06.017 · Cited by 42
Langerhans cells and NK cells cooperate in the inhibition of chemical skin carcinogenesis
Ortner, D., Tripp, C. H., Komenda, K., Dubrac, S., Zelger, B., Hermann, M., Doppler, W., Tymoszuk, P., Boon, L., Clausen, B. E., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1260215 · Cited by 41
NKG2D splice variants: a reexamination of adaptor molecule associations
Rabinovich, B. A., Li, J. S. Y., Wolfson, M. F., Lawrence, W., Beers, C., Chalupny, J., Hurren, R., Greenfield, B., Miller, R. G., & Cosman, D. J. (2006) · Immunogenetics · doi:10.1007/s00251-005-0078-x · Cited by 41
Belting, L., Hömberg, N., Przewoznik, M., Brenner, C., Riedel, T., Flatley, A., Polić, B., Busch, D. H., Röcken, M., & Mocikat, R. (2015) · European Journal of Immunology · doi:10.1002/eji.201445375 · Cited by 40
Protein Kinase C-θ Is Required for NK Cell Activation and In Vivo Control of Tumor Progression
Aguiló, J. I., Garaude, J., Pardo, J., Villalba, M., & Anel, A. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801820 · Cited by 40
Walsh, K. B., Lanier, L. L., & Lane, T. E. (2007) · Journal of Virology · doi:10.1128/jvi.02033-07 · Cited by 40
Self-citationGirardi, M., Oppenheim, D. E., Glusac, E. J., Filler, R. B., Balmain, A., Tigelaar, R. E., & Hayday, A. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.22342.x · Cited by 40
Okita, R., Wolf, D., Yasuda, K., Maeda, A., Yukawa, T., Saisho, S., Shimizu, K., Yamaguchi, Y., Oka, M., Nakayama, E., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139809 · Cited by 39
“Thus, the balance between NKG2D ligands and MHC class I expression on transformed cells is important for their survival during immune surveillance of their host [14].”
BackgroundImmunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer
Peipp, M., Klausz, K., Boje, A. S., Zeller, T., Zielonka, S., & Kellner, C. (2022) · Clinical & Experimental Immunology · doi:10.1093/cei/uxac028 · Cited by 39
Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer
Arina, A., Murillo, O., Dubrot, J., Azpilikueta, A., Alfaro, C., Perez‐Gracia, J. L., Bendandi, M., Palencia, B., Hervás‐Stubbs, S., & Melero, I. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.5.599 · Cited by 39
NKG2D in Innate and Adaptive Immunity
Lanier, L. L. (2005) · Advances in experimental medicine and biology · doi:10.1007/0-387-24180-9_7 · Cited by 39
Self-citationImmune Control in Hepatocellular Carcinoma Development and Progression: Role of Stromal Cells
Sprinzl, M. F., & Galle, P. R. (2014) · Seminars in Liver Disease · doi:10.1055/s-0034-1394138 · Cited by 38
Maccalli, C., Nonaka, D., Piris, A., Pende, D., Rivoltini, L., Castelli, C., & Parmiani, G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1166 · Cited by 38
Natural killer cell‐mediated lysis of freshly isolated human tumor cells
Carlsten, M., Malmberg, K., & Ljunggren, H. (2008) · International Journal of Cancer · doi:10.1002/ijc.24082 · Cited by 39
Koh, C. Y., Ortaldo, J. R., Blazar, B. R., Bennett, M., & Murphy, W. J. (2003) · Blood · doi:10.1182/blood-2003-04-1367 · Cited by 38
Chang, C., & Ferrone, S. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.001 · Cited by 38
NK Cell Interaction With Platelets and Myeloid Cells in the Tumor Milieu
Maurer, S., & de Andrade, L. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.608849 · Cited by 37
New directions in natural killer cell-based immunotherapy of human cancer
Farag, S. S., Fehniger, T. A., Becknell, B., Blaser, B. W., & Caligiuri, M. A. (2003) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.3.2.237 · Cited by 37
Activation of Cytotoxic and Regulatory Functions of NK Cells by Sindbis Viral Vectors
Granot, T., Venticinque, L., Tseng, J., & Meruelo, D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020598 · Cited by 36
Rodríguez, T., M�ndez, R., Roberts, C. H., Ruiz‐Cabello, F., Dodi, I. A., López‐Nevot, M. Á., Paco, L., Maleno, I., Marsh, S. G. E., Pawelec, G., et al. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0561-5 · Cited by 36
Chronotherapy of colorectal cancer
Giacchetti, S. (2002) · Chronobiology International · doi:10.1081/cbi-120002602 · Cited by 36
Belicha‐Villanueva, A., Riddell, J. R., Bangia, N., & Gollnick, S. O. (2012) · Lasers in Surgery and Medicine · doi:10.1002/lsm.21160 · Cited by 36
Paschen, A., Baingo, J., & Schadendorf, D. (2014) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2014.01.009 · Cited by 35
Jachimowicz, R. D., Fracasso, G., Yazaki, P. J., Power, B. E., Borchmann, P., Engert, A., Hansen, H. P., Reiners, K. S., Madlener, M., von Strandmann, E. P., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1093 · Cited by 35
Maintaining the Balance: Regulation of NK Cell Activity
Imširović, V., Wensveen, F. M., Polić, B., & Jelenčić, V. (2024) · Cells · doi:10.3390/cells13171464 · Cited by 34
Mantovani, S., Varchetta, S., Mele, D., Donadon, M., Torzilli, G., Soldani, C., Franceschini, B., Porta, C., Chiellino, S., Pedrazzoli, P., et al. (2020) · Cancers · doi:10.3390/cancers12123583 · Cited by 34
Regulation of Human DAP10 Gene Expression in NK and T Cells by Ap-1 Transcription Factors
Marusina, A. I., Burgess, S. J., Pathmanathan, I., Borrego, F., & Coligan, J. E. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.1.409 · Cited by 34
Natural killer cell receptors: Regulating innate immune responses to hematologic malignancy
Hsu, K. C., & Dupont, B. (2005) · Seminars in Hematology · doi:10.1053/j.seminhematol.2005.01.010 · Cited by 34
Elimination In Vivo of Developing T Cells by Natural Killer Cells
Schott, E., Bonasio, R., & Ploegh, H. L. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030918 · Cited by 34
In vivo tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity
Prchal‐Murphy, M., Witalisz‐Siepracka, A., Bednarik, K., Putz, E. M., Gotthardt, D., Meissl, K., Sexl, V., Müller, M. M., & Strobl, B. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1047579 · Cited by 33
Dissecting the Role of Bone Marrow Stromal Cells on Bone Metastases
Buenrostro, D., Park, S. I., & Sterling, J. A. R. (2014) · BioMed Research International · doi:10.1155/2014/875305 · Cited by 34
Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy
Ding, H., Yang, X., & Wei, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010177 · Cited by 33
Killing the Invaders: NK Cell Impact in Tumors and Anti-Tumor Therapy
Molgora, M., Cortez, V. S., & Colonna, M. (2021) · Cancers · doi:10.3390/cancers13040595 · Cited by 33
The balancing act: Inhibitory Ly49 regulate NKG2D-mediated NK cell functions
Malarkannan, S. (2006) · Seminars in Immunology · doi:10.1016/j.smim.2006.04.002 · Cited by 33
Holdenrieder, S., Eichhorn, P., Beuers, U. H., Samtleben, W., Stieber, P., Nagel, D., Peterfi, A., Steinle, A., & Salih, H. R. (2007) · PubMed · Cited by 33
Brehm, M. A., Daniels, K. A., Ortaldo, J. R., & Welsh, R. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.11.6663 · Cited by 33
Regulation of Natural Killer Cell Function
Makrigiannis, A. P., & Anderson, S. K. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.2.6.560 · Cited by 33
Cutting Edge: The Minor Histocompatibility Antigen H60 Peptide Interacts with Both H-2Kb and NKG2D
Cerwenka, A., O’Callaghan, C. A., Hamerman, J. A., Yadav, R., Ajayi, W. U., Roopenian, D. C., Joyce, S., & Lanier, L. L. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.7.3131 · Cited by 31
Self-citationNKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity
Hérault, A., Mak, J., Cruz-Chuh, J. D., Dillon, M. A., Ellerman, D. A., Go, M., Cosino, E., Clark, R., Carson, E., Yeung, S., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03795-2 · Cited by 30
Satwani, P., Bavishi, S., Saha, A., Zhao, F., Ayello, J. S., van de Ven, C., Chu, Y., & Cairo, M. S. (2014) · Cytotherapy · doi:10.1016/j.jcyt.2014.03.008 · Cited by 30
Yokoyama, W. M., & Riley, J. K. (2008) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)60573-1 · Cited by 30
Restoration of antitumor immunity through anti-MICA antibodies elicited with a chimeric protein
Torres, N., Regge, M. V., Secchiari, F., Friedrich, A. D., Spallanzani, R. G., Raffo Iraolagoitia, X. L., Núñez, S. Y., Sierra, J. M., Ziblat, A., Santilli, M. C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000233 · Cited by 29
Convergent Evolution by Cancer and Viruses in Evading the NKG2D Immune Response
Baugh, R. T., Khalique, H., & Seymour, L. W. (2020) · Cancers · doi:10.3390/cancers12123827 · Cited by 29
de Kruijf, E. M., Engels, C. C., van de Water, W., Bastiaannet, E., Smit, V. T. H. B. M., van de Velde, C. J. �., Liefers, G., & Kuppen, P. J. K. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2752-2 · Cited by 29
Imbalance of NKG2D and its inhibitory counterparts: How does tumor escape from innate immunity?
Zhang, C., Zhang, J., Wei, H., & Tian, Z. (2005) · International Immunopharmacology · doi:10.1016/j.intimp.2005.03.003 · Cited by 29
4-1BB regulates NKG2D costimulation in human cord blood CD8+ T cells
Kim, Y., Han, M., & Broxmeyer, H. E. (2007) · Blood · doi:10.1182/blood-2007-01-069450 · Cited by 29
Hoover, R. G., Gullickson, G., & Kornbluth, J. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00393 · Cited by 29
A Nonclassical MHC Class I Molecule Restricts CTL-Mediated Rejection of a Syngeneic Melanoma Tumor
Chiang, E. Y., & Stroynowski, I. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.7.4394 · Cited by 29
Plaza-Rojas, L., & Guevara-Patino, J. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.624131 · Cited by 32
Cheng, M., Charoudeh, H. N., Brodin, P., Tang, Y., Lakshmikanth, T., Höglund, P., Jacobsen, S. E. W., & Sitnicka, E. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.3.1460 · Cited by 27
Engels, C. C., Fontein, D. B. Y., Kuppen, P. J. K., de Kruijf, E. M., Smit, V. T. H. B. M., Nortier, J. W. R., Liefers, G., van de Velde, C. J. �., & Bastiaannet, E. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.338 · Cited by 27
Cho, H.-M., Rosenblatt, J. D., Tolba, K. A., Shin, S. J., Shin, D. S., Calfa, C., Zhang, Y., & Shin, S.-U. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1047 · Cited by 27
Wagner, A. K., Wickström, S. L., Tallerico, R., Salam, S., Lakshmikanth, T., Brauner, H., Höglund, P., Carbone, E., Johansson, M. H., & Kärre, K. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0001 · Cited by 27
A DNA-based cancer vaccine enhances lymphocyte cross talk by engaging the NKG2D receptor
Zhou, H., Luo, Y., Kaplan, C., Krüger, J. A., Lee, S., Xiang, R., & Reisfeld, R. A. (2005) · Blood · doi:10.1182/blood-2005-10-4231 · Cited by 27
DNA Damage and Tumor Surveillance: One Trigger for Two Pathways
Höglund, P. (2006) · Science s STKE · doi:10.1126/stke.3172006pe2 · Cited by 27
Targeting NKG2D in tumor surveillance
Hayakawa, Y. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.681378 · Cited by 26
Jin, F., Lin, H. P., Gao, S., Hu, Z., Zuo, S., Liguang, S., Jin, C., Li, W., & Yang, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.13007 · Cited by 26
Gallaher, J. A., Larripa, K., Renardy, M., Shtylla, B., Tania, N., White, D., Wood, K., Zhu, L., Passey, C., Robbins, M. D. H., et al. (2018) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2018.08.037 · Cited by 26
Regulatory Role for NK Cells in a Mouse Model of Systemic Juvenile Idiopathic Arthritis
Vandenhaute, J., Avau, A., Filtjens, J., Malengier‐Devlies, B., Imbrechts, M., den Berghe, N. V., Ahmadzadeh, K., Mitera, T., Boon, L., Leclercq, G., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900510 · Cited by 26
STAT1 Isoforms Differentially Regulate NK Cell Maturation and Anti-tumor Activity
Meissl, K., Simonović, N., Amenitsch, L., Witalisz‐Siepracka, A., Klein, K., Lassnig, C., Puga, A., Vogl, C., Poelzl, A., Bosmann, M., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02189 · Cited by 26
Beilke, J. N., Benjamin, J., & Lanier, L. L. (2010) · Blood · doi:10.1182/blood-2010-05-285031 · Cited by 26
Self-citationChitadze, G., & Kabelitz, D. (2022) · Scandinavian Journal of Immunology · doi:10.1111/sji.13201 · Cited by 25
Himmelreich, H., Mathys-Schneeberger, A., Wodnar‐Filipowicz, A., & Kalberer, C. P. (2011) · Human Immunology · doi:10.1016/j.humimm.2011.03.005 · Cited by 25
Natural Killer Cells Require Selectins for Suppression of Subcutaneous Tumors
Sobolev, O., Stern, P., Lacy‐Hulbert, A., & Hynes, R. O. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3126 · Cited by 26
Shimizu, T., Tomogane, M., Miyashita, M., Ukimura, O., & Ashihara, E. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1424671 · Cited by 25
Tran, P. D., Christiansen, D., Winterhalter, A. C., Brööks, A. G., Gorrell, M. D., Lilienfeld, B. G., Seebach, J. D., Sandrin, M. S., & Sharland, A. F. (2008) · Xenotransplantation · doi:10.1111/j.1399-3089.2008.00489.x · Cited by 25
Masuda, H., Saeki, Y., Nomura, M., Shida, K., Matsumoto, M., Ui, M., Lanier, L. L., & Seya, T. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.6165 · Cited by 25
Self-citationFarooqi, A. A., Attar, R., Ishmuratova, M., & Berardi, R. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2021.05.029 · Cited by 24
NK cells do not mediate renal injury in murine adriamycin nephropathy
Zheng, G., Zheng, L., Wang, Y., Wu, H., Kairaitis, L., Zhang, C., Tay, Y., Wang, Y., Alexander, S. I., & Harris, D. C. H. (2006) · Kidney International · doi:10.1038/sj.ki.5000244 · Cited by 24
Basher, F., Jeng, E. K., Wong, H. C., & Wu, J. D. (2015) · Oncotarget · doi:10.18632/oncotarget.6416 · Cited by 24
The Biological Influence and Clinical Relevance of Polymorphism Within the NKG2D Ligands
Zuo, J., Mohammed, F., & Moss, P. A. H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01820 · Cited by 24
Impaired intratumoral natural killer cell function in head and neck carcinoma
Mele, D., Pessino, G., Trisolini, G., Luchena, A., Benazzo, M., Morbini, P., Mantovani, S., Oliviero, B., Mondelli, M. U., & Varchetta, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.997806 · Cited by 24
Hu, J., Bernatchez, C., Zhang, L., Xia, X., Kleinerman, E. S., Hung, M., Hwu, P., & Li, S. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0234 · Cited by 24
In vivo immunogenetics: from MIC to RAET1 loci
Radosavljevic, M., & Bahram, S. (2003) · Immunogenetics · doi:10.1007/s00251-003-0546-0 · Cited by 24
Alli, R., Savithri, B., Das, S., Varalakshmi, C., Rangaraj, N., & Khar, A. (2004) · European Journal of Immunology · doi:10.1002/eji.200324793 · Cited by 24
Impaired tumor rejection by memory CD8 T cells in mice with NKG2D dysfunction
Andre, M. C., Sigurdardottir, D., Kuttruff, S., Pömmerl, B., Handgretinger, R., Rammensee, H., & Steinle, A. (2011) · International Journal of Cancer · doi:10.1002/ijc.26191 · Cited by 23
Dhar, P., Basher, F., Ji, Z., Huang, L., Qin, S., Wainwright, D. A., Robinson, J. W., Hagler, S. B., Zhou, J., Mackay, S., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02440-3 · Cited by 23
Abdool, K., Cretney, E., Brooks, A. D., Kelly, J. M., Swann, J. B., Shanker, A., Bere, E. W., Yokoyama, W. M., Ortaldo, J. R., Smyth, M. J., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.4.2575 · Cited by 23
Physiological roles of murine DAP10 adapter protein in tumor immunity and autoimmunity
Hyka‐Nouspikel, N., & Phillips, J. H. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00456.x · Cited by 23
Lipsitch, M., Eyal, N., Halloran, M. E., Hernán, M. Á., Longini, I. M., Perencevich, E. N., & Grais, R. F. (2015) · Science · doi:10.1126/science.aaa3178 · Cited by 22
Kim, Y.-H., Born, C., Bléry, M., & Steinle, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00960 · Cited by 22
Practical considerations for chimeric antigen receptor design and delivery
Oldham, R. A. A., & Medin, J. A. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1339687 · Cited by 22
Kim, T.-J., Upadhyay, V., Kumar, V., Lee, K., & Fu, Y. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20131501 · Cited by 21
Simonović, N., Witalisz‐Siepracka, A., Meissl, K., Lassnig, C., Reichart, U., Kolbe, T., Farlik, M., Bock, C., Sexl, V., Müller, M. M., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1701649 · Cited by 21
The role of dendritic cells for therapy of B-cell lymphoma with immune checkpoint inhibitors
Scheuerpflug, A., Ahmetlić, F., Bauer, V., Riedel, T., Röcken, M., & Mocikat, R. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02767-6 · Cited by 21
Lawrence, D. W., Willard, P. A., Cochran, A. M., Matchett, E. C., & Kornbluth, J. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.573372 · Cited by 21
E- and P-Selectins Synergistically Inhibit Bleomycin-Induced Pulmonary Fibrosis
Horikawa, M., Fujimoto, M., Hasegawa, M., Matsushita, T., Hamaguchi, Y., Kawasuji, A., Matsushita, Y., Fujita, T., Ogawa, F., Takehara, K., et al. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.060086 · Cited by 21
Walsh, K. B., Lodoen, M. B., Edwards, R. A., Lanier, L. L., & Lane, T. E. (2007) · Journal of Virology · doi:10.1128/jvi.02032-07 · Cited by 21
Self-citationNK cells vs. obesity: A tale of dysfunction & redemption
Barra, C. D., O'Shea, D. B., & Hogan, A. E. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109744 · Cited by 21
Xie, W., Liu, F., Wang, Y., Ren, X., Wang, T., Chen, Z., Tang, M., Sun, F., Li, Z., Wang, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7501 · Cited by 20
Metadata
- Authors
- Cerwenka, A., Baron, J. L., & Lanier, L. L.
- Affiliations
- University of California, San Francisco (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2001-09-18
- Volume
- 98
- Issue
- 20
- Pages
- 11521-11526
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC58762
- OpenAlex
- W2056645320
- Cited by
- 606
- References
- 34
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 11 · 2023: 11 · 2022: 20 · 2021: 15 · 2020: 24 · 2019: 17 · 2018: 15 · 2017: 26 · 2016: 14 · 2015: 22 · 2014: 27 · 2013: 25 · 2012: 24
- FWCI
- 10.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- National Institutes of Health
- National Cancer Institute (CA89189, R01CA089189)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Keywords
- Rae1, NKG2D, natural killer cells, MHC class I, tumor rejection, missing self, NK cell receptors, immune surveillance, NK1.1+ T cells, tumor rechallenge
- MeSH terms
- Animals, B-Lymphocytes, Female, Immunoglobulin Fc Fragments, Immunologic Memory, Killer Cells, Natural, Lymphocyte Depletion, Lymphoma, Major Histocompatibility Complex, Membrane Proteins, Mice, Inbred C57BL, Recombinant Fusion Proteins, Transfection, Tumor Cells, Cultured, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.